General clinical practice intraoperative intravesical epirubicin: implementing the process

Area of Science:

• Urology
• Oncology
• Cancer Research

Background:

• Stage Ta and T1 bladder cancer requires prompt treatment post-surgery.
• Intravesical chemotherapy instillation within 6 hours of transurethral resection of bladder tumor (TURBT) is a standard recommendation.
• Adherence to this guideline is crucial for improving patient outcomes.

Purpose of the Study:

• To describe the practical implementation of intraoperative epirubicin instillation.
• To standardize the process within a hospital setting.
• To ensure timely administration of adjuvant therapy for non-muscle invasive bladder cancer.

Main Methods:

• Intraoperative instillation of epirubicin following TURBT.
• Standardized protocol for drug preparation and administration.
• Quality assurance measures for the procedure.

Main Results:

• Successful integration of intraoperative chemotherapy instillation into surgical workflow.
• Consistent administration of epirubicin post-TURBT.
• Facilitation of guideline adherence in clinical practice.

Conclusions:

• Intraoperative epirubicin instillation is a feasible and effective method for treating stage Ta-T1 bladder cancer.
• This approach ensures timely delivery of adjuvant chemotherapy.
• The described implementation provides a model for other institutions.